Source: International Congress 2019 – State of the art session: Pulmonary vascular diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Ghofrani (Gießen, Germany). Lessons learned from trials of anti-remodelling drugs in pulmonary arterial hypertension. International Congress 2019 – State of the art session: Pulmonary vascular diseases

Member's Comments

No comment yet.

Related content which might interest you: Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 Challenging the concept of adding more drugs in pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701527; 10.1183/13993003.01527-2017 Year: 2017 Do we need controlled clinical trials in pulmonary arterial hypertension? Source: Eur Respir J 2001; 17: 1-3 Year: 2001 New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 495-502 Year: 2013 Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Repurposing benzbromarone for pulmonary arterial hypertension: can channelling the past deliver the therapy of the future? Source: Eur Respir J, 53 (6) 1900583; 10.1183/13993003.00583-2019 Year: 2019 Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights Source: Eur Respir J 2015; 46: 414-421 Year: 2015 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 Pathogenesis of pulmonary arterial hypertension: lessons from cancer Source: Eur Respir Rev 2013; 22: 543-551 Year: 2013 Current medical treatment of pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 Current medical treatment of pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Current medical treatment of pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Current medical treatment of pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014